Huang Guangliang, Yan Yuchi, He Wenjuan, et al. Evidence-Based Pharmacoeconomic Evaluation of Peramivir in the Treatment of Influenza in Children. [J]. 28(2):8-11(2022)
DOI:
Huang Guangliang, Yan Yuchi, He Wenjuan, et al. Evidence-Based Pharmacoeconomic Evaluation of Peramivir in the Treatment of Influenza in Children. [J]. 28(2):8-11(2022) DOI: 10.13407/ j.cnki.jpp.1672-108X.2022.02.003.
Evidence-Based Pharmacoeconomic Evaluation of Peramivir in the Treatment of Influenza in Children
目的:探讨静脉滴注帕拉米韦相较于口服奥司他韦在治疗儿童流行性感冒的有效性、安全性和经济性。方法:计算机检索中国知网、中国生物医学文献数据库、维普、万方数据库、PubMed、the Cochrane Library、Web of Science等中英文数据库。根据纳入标准和排除标准,筛选符合要求的帕拉米韦对比奥司他韦治疗儿童流行性感冒的随机对照试验,文献质量评价根据Cochrane协作网提供的质量评估标准进行,终点观测指标由RevMan 5.4软件进行Meta分析,使用成本-效果分析法对所得结果进行经济学评价。结果:临床有效率和不良事件发生率两组比较差异均有统计学意义(RR=1.11,95% CI 1.07~1.15,Z=5.14,P<0.000 01;RR=0.66,95% CI 0.47~0.94,P=0.02)。在经济学方面,以帕拉米韦用药时间和不同儿童体质量分别组合得出不同的ICER值,帕拉米韦单次用药的增量成本效益比(ICER)值分别为体质量≤15 kg,ICER=3.81;体质量>15~23 kg,ICER=5.72;体质量>23~40 kg,ICER=1.15;体质量>40 kg,ICER=-3.41。结论:在治疗儿童流行性感冒的过程中,帕拉米韦相比于奥司他韦在有效率和不良事件发生率上均占有优势;在经济学方面,奥司他韦普遍占有优势,帕拉米韦仅在单次用药时具有成本-效果比。
Abstract
Objective: To probe into the differences for efficacy
safety and economy of intravenous peramivir and oral oseltamivir in the treatment of influenza in children. Methods: CNKI
CBM
VIP
Wanfang
PubMed
the Cochrane Library and Web of Science database were retrieved. According to the inclusion and exclusion criteria
the eligible randomized controlled trials of peramivir versus oseltamivir in the treatment of influenza in children were screened. Literature quality was evaluated according to the quality assessment criteria provided by the Cochrane system evaluation standard. The endpoint observation indicators were obtained by Meta analysis with RevMan 5.4 software
and the results were evaluated economically by cost-effectiveness analysis. Results: There were significant differences between two groups in clinical effective rate and incidence of adverse events (RR=1.11
95%CI from 1.07 to 1.15
Z=5.14
P<0.000
01; RR=0.66
95%CI from 0.47 to 0.94
P=0.02). In terms of economics
different incremental cost-effectiveness ratio (ICER) values were derived by combining the duration of paramivir dosing and different body mass in children
respectively. The ICER values for single dose of peramivir were body mass ≤15 kg
ICER=3.81; body mass >15 to 23 kg
ICER=5.72; body mass >23 to 40 kg
ICER=1.15; body mass >40 kg
ICER=-3.41. Conclusion: Compared with oseltamivir
peramivir has advantages in the effective rate and incidence of adverse events in the treatment of influenza in children; in terms of economics
oseltamivir generally held an advantage
with paramivir having a cost-effectiveness ratio advantage only at single dose.
Analysis of 36 Cases of Drug Poisoning in Children in a Grade III, Level A General Hospital andConsideration on Pharmaceutical Care
Application of Dexmedetomidine Combined with Hydromorphone Nasal Drip in Sedation of Mother-InfantSeparation before Adenoidectomy
Sirolimus in the Treatment of 5 Cases of Blue Rubber Bleb Nevus Syndrome in Children and Literature Review
Systematic Review on Efficacy and Safety of Zoledronic Acid in the Treatment of Bone Metabolic Disordersin Children
Drug Utilization Evaluation of Voriconazole for Injection in Children Based on Weighted Technique for Order Preference by Similarity to Ideal Solution Method
Related Author
Wang Peng
Xu Ying
Zhang Xiaoming
Zhang Shaonan
Li Changsong
Li Yunxiang
Li Xiaojing
Sun Canlin
Related Institution
The Second People’ s Hospital of Anhui Wuhu, Anhui Wuhu